IP Library Granted Patent US 11,110,053
Granted Patent B2
US 11,110,053 · App. 15/692,694 · Granted Sep 7, 2021

Compositions and methods for the prevention and treatment of cardiovascular diseases

Inventors: Henk Van Wyk (Denver, CO); Mariette Van Wyk (Denver, CO); Trace Krebs (Sarasota, FL); Peter Lange (Denver, CO); Brian Denomme (Northville, MI); Michael A. Volk (Broomfield, CO)
Assignee: REVEN PHARMACEUTICALS INC.
A61K9/0019A61K31/16A61K31/167A61K31/341A61K31/375A61K31/4415A61K31/455A61K31/51A61K31/519A61K31/525A61K31/555A61K31/675A61K31/714A61K33/00A61K33/06A61K33/14A61K41/0047
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,110,053
App. No.
15/692,694
Granted
Sep 7, 2021
Kind
B2
Abstract

Compositions comprising electro-activated aqueous solutions and methods for the prevention and treatment of dysfunctional cardiovascular conditions are provided.

Claims (17)

1. A therapeutic composition consisting of:

an electro-activated solution with a stable negative oxidation-reduction potential in a range between 50 mV and 500 mV, a conductivity between 11 and 15 mS/cm and a pH in the range between 6.5 and 7.6, the electro-activated solution consisting of:

0.5-10% magnesium sulfate hexahydrate;

5.0-20% ascorbic acid;

0.2-2.0% niacinamide;

0.2-2% pyridoxin HCl;

0.01-2.0% calcium D pantothenate;

0.1-1.0% thiamin HCl;

0.01-0.1% riboflavin;

0.001-0.1% cyanocobalamin;

0.5-10% sodium bicarbonate; 0.8-1% sodium chloride; and electrochemically activated water.

2. The composition of claim 1 , wherein the magnesium sulfate hexahydrate is at 0.05-0.075%.

3. A therapeutic composition consisting of the product of a method of preparing a therapeutic composition with a stable negative oxidation-reduction potential in a range between −50 mV and −900 mV, a conductivity between 11 and 15 mS/cm and a pH in the range between 6.5 and 7.6, the method comprising:

mixing a first electroactivated solution with a second electroactivated solution, the first electroactivated solution having a stable negative oxidation-reduction potential and the second electroactivated solution having a stable positive oxication oxidation-reduction potential, wherein

the first electroactivated solution has an oxidation-reduction potential in the range between −500 mV and −900 mV for a period of at least 12 months and a pH in the range between 3.2 and 4.5, and one liter of the first electroactivated solution consists of: 83.6-95.5 g/L ascorbic acid; 57.1-64.7 g/L magnesium sulfate hexahydrate; 9.4-10.6 g/L niacinamide; 9.4-10.6 g/L pyridoxin HCl; 0.18-0.29 g/L riboflavin-5-phosphate sodium; 5.75-6.5 g/L thiamin HCl; 0.17-0.2 g/L cyanocobalamin crystalline; and electrochemically activated water,

the second electroactivated solution has an oxidation-reduction potential in the range between +500 mV and +900 mV for a period of at least 12 months and a pH in the range between 6.5 and 7.8, and one liter of the second electroactivated solution consists of: 82.4-93.2 g/L sodium bicarbonate USP, 19.1-21.8 g/L magnesium sulfate hexahydrate; and electrochemically activated water,

and the step of mixing comprises mixing equal volumes of the first electroactivated solution and the second electroactivated solution.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 2, 2019
From: VAN WYK, HENK; VAN WYK, MARIETTE; KREBS, TRACY L; LANGE, PETER B; DENOMME, BRIAN; VOLK, MICHAEL A
To: NOVENTIS, INC.
Reel/Frame 050605/0489 →
CHANGE OF ASSIGNEE'S ADDRESS Recorded Oct 2, 2019
From: REVEN PHARMACEUTICALS, INC.
To: REVEN PHARMACEUTICALS, INC.
Reel/Frame 050611/0074 →
CHANGE OF NAME Recorded Oct 2, 2019
From: NOVENTIS, INC.
To: REVEN PHARMACEUTICALS, INC.
Reel/Frame 050611/0084 →
Continuity (4)
Continuation 14550677 · Nov 21, 2014
Division 13055691
Provisional Application 61129883 · Jul 25, 2008
Related Publication 20170360696A1 · Dec 21, 2017